Christina Yeon

594 total citations
26 papers, 367 citations indexed

About

Christina Yeon is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Christina Yeon has authored 26 papers receiving a total of 367 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 9 papers in Cancer Research. Recurrent topics in Christina Yeon's work include Cancer Treatment and Pharmacology (11 papers), HER2/EGFR in Cancer Research (8 papers) and Advanced Breast Cancer Therapies (7 papers). Christina Yeon is often cited by papers focused on Cancer Treatment and Pharmacology (11 papers), HER2/EGFR in Cancer Research (8 papers) and Advanced Breast Cancer Therapies (7 papers). Christina Yeon collaborates with scholars based in United States, Germany and France. Christina Yeon's co-authors include Mark D. Pegram, Cary A. Presant, Behnam Ebrahimi, Linda D. Bosserman, R. C. Horns, Frank L. Howard, Paul Frankel, Yuan Yuan, Mina S. Sedrak and Joanne Mortimer and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Christina Yeon

26 papers receiving 354 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Christina Yeon United States	8	258	97	85	76	70	26	367
Zoneddy Dayao United States	12	231 0.9×	105 1.1×	62 0.7×	56 0.7×	153 2.2×	26	400
Sasha Lupichuk Canada	10	157 0.6×	64 0.7×	45 0.5×	86 1.1×	79 1.1×	29	328
Claudia Arce-Salinas Mexico	11	241 0.9×	80 0.8×	64 0.8×	138 1.8×	177 2.5×	25	448
Т. Yu. Semiglazova Russia	7	237 0.9×	79 0.8×	34 0.4×	57 0.8×	71 1.0×	140	367
Sandeep Sehdev Canada	13	272 1.1×	122 1.3×	40 0.5×	54 0.7×	201 2.9×	35	451
Louise M. Rasmussen Denmark	8	150 0.6×	50 0.5×	120 1.4×	155 2.0×	54 0.8×	8	487
Lorenzo Rossi Switzerland	10	192 0.7×	110 1.1×	33 0.4×	90 1.2×	99 1.4×	30	402
Friedrich Overkamp Germany	13	356 1.4×	204 2.1×	40 0.5×	149 2.0×	206 2.9×	64	592
Katherine Clifton United States	10	194 0.8×	113 1.2×	20 0.2×	80 1.1×	106 1.5×	41	398
Valérie Cristina Switzerland	7	175 0.7×	101 1.0×	22 0.3×	70 0.9×	35 0.5×	15	364

Countries citing papers authored by Christina Yeon

Since Specialization

Citations

This map shows the geographic impact of Christina Yeon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christina Yeon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christina Yeon more than expected).

Fields of papers citing papers by Christina Yeon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christina Yeon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christina Yeon. The network helps show where Christina Yeon may publish in the future.

Co-authorship network of co-authors of Christina Yeon

This figure shows the co-authorship network connecting the top 25 collaborators of Christina Yeon. A scholar is included among the top collaborators of Christina Yeon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christina Yeon. Christina Yeon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Egelston, Colt A., Susan E. Yost, Paul Frankel, et al.. (2024). A phase I/II trial of palbociclib, pembrolizumab, and endocrine therapy for patients with HR+/HER2- locally advanced or metastatic breast cancer (MBC): Clinical outcomes and stool microbial profiling.. Journal of Clinical Oncology. 42(16_suppl). 1038–1038. 1 indexed citations

Lavasani, Sayeh, George Somlo, Susan E. Yost, et al.. (2022). Phase 2 prospective open label study of neoadjuvant nab‐paclitaxel, trastuzumab, and pertuzumab in patients with HER2‐positive primary breast cancer. Cancer. 129(5). 740–749. 5 indexed citations

Moore, Halle C. F., William E. Barlow, George Somlo, et al.. (2021). A Randomized Trial of Fulvestrant, Everolimus, and Anastrozole for the Front-line Treatment of Patients with Advanced Hormone Receptor–positive Breast Cancer, SWOG S1222. Clinical Cancer Research. 28(4). 611–617. 8 indexed citations

Yuan, Yuan, Jin Sun Lee, Susan E. Yost, et al.. (2021). Phase I/II trial of palbociclib, pembrolizumab and letrozole in patients with hormone receptor-positive metastatic breast cancer. European Journal of Cancer. 154. 11–20. 61 indexed citations

Mortimer, Joanne, Laura Kruper, Mary Cianfrocca, et al.. (2020). Use of HER2-Directed Therapy in Metastatic Breast Cancer and How Community Physicians Collaborate to Improve Care. Journal of Clinical Medicine. 9(6). 1984–1984. 3 indexed citations

Liu, Jennifer, Simran Padam, Daneng Li, et al.. (2020). Strategies to Improve Participation of Older Adults in Cancer Research. Journal of Clinical Medicine. 9(5). 1571–1571. 17 indexed citations

Durm, Greg Andrew, Sandra K. Althouse, Salma K. Jabbour, et al.. (2019). P1.18-05 ChemoXRT W/ Consolidation Pembrolizumab in Unresectable Stage III NSCLC: Long-Term Survival Update and Analysis of Post-Progression Therapy. Journal of Thoracic Oncology. 14(10). S627–S627. 1 indexed citations

Yuan, Yuan, Paul Frankel, Laura Kruper, et al.. (2019). Abstract P1-15-07: Phase II trial of neoadjuvant carboplatin and nab-paclitaxel in patients with locally advanced triple negative breast cancer. Cancer Research. 79(4_Supplement). P1–15. 1 indexed citations

Chung, Vincent, Paul Frankel, Dean Lim, et al.. (2016). Phase Ib Trial of mFOLFOX6 and Everolimus (NSC-733504) in Patients with Metastatic Gastroesophageal Adenocarcinoma. Oncology. 90(6). 307–312. 7 indexed citations

10.

Ashing, Kimlin, Dalnim Cho, Lily Lai, et al.. (2016). Exploring characteristics, predictors, and consequences of fear of cancer recurrence among Asian‐American breast cancer survivors. Psycho-Oncology. 26(12). 2253–2260. 27 indexed citations

11.

Somlo, George, Sei Y. Chung, Paul Frankel, et al.. (2016). Abstract P1-14-10: Phase II trial of neoadjuvant chemotherapy with carboplatin and nab-paclitaxel in patients with triple negative locally advanced and inflammatory breast cancer. Cancer Research. 76(4_Supplement). P1–14. 2 indexed citations

12.

Presant, Cary A., Linda D. Bosserman, R. C. Horns, et al.. (2007). Aromatase Inhibitor–Associated Arthralgia and/or Bone Pain: Frequency and Characterization in Non–Clinical Trial Patients. Clinical Breast Cancer. 7(10). 775–778. 93 indexed citations

13.

Pegram, Mark D., Vera Therezinha Medeiros Borges, Jyotsna Fuloria, et al.. (2006). Phase I pharmacokinetics (PK) of humanized anti-MUC-1 antibody R1550. Journal of Clinical Oncology. 24(18_suppl). 2533–2533. 3 indexed citations

14.

Presant, Cary A., Christine Kelly, Linda D. Bosserman, et al.. (2006). Aromatase inhibitor (AI)-associated arthralgia (A) and bone pain (BP): Frequency and characterization in clinical practice. Journal of Clinical Oncology. 24(18_suppl). 6137–6137. 14 indexed citations

15.

Bosserman, Linda D., Cary A. Presant, Cynthia L. Martel, et al.. (2005). Increasing accrual (Ac) to clinical trials (CT) in community cancer clinics (CCC): A successful method using electronic medical records (EMR), virtual private network (VPN) and focused group activities (FGA). Journal of Clinical Oncology. 23(16_suppl). 6088–6088. 1 indexed citations

16.

Yeon, Christina & Mark D. Pegram. (2005). Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer. Investigational New Drugs. 23(5). 391–409. 74 indexed citations

17.

Martel, Cynthia L., Bahram Ebrahimi, R. C. Horns, et al.. (2005). Incidence of bevacizumab (BE) related toxicities: Association of hypertension (HTN) and proteinuria (PTN), a BE toxicity syndrome (BETS). Journal of Clinical Oncology. 23(16_suppl). 8062–8062. 5 indexed citations

18.

Slamon, DJ, Christina Yeon, Tadeusz Pieńkowski, et al.. (2004). Survival analysis from two open-label non-randomized phase II trials of trastuzumab (H) combined with docetaxel (T) and platinums (C, cisplatin or carboplatin) (TCH) in women with HER2+ advanced breast cancer (ABC). Journal of Clinical Oncology. 22(14_suppl). 642–642. 6 indexed citations

19.

Yeon, Christina, DJ Slamon, Reema Patel, et al.. (2004). Clinical benefit of trastuzumab (H) among patients with HER2-positive metastatic breast cancer (MBC) not achieving objective responses when treated with H plus chemotherapy (CT). Journal of Clinical Oncology. 22(14_suppl). 680–680. 6 indexed citations

20.

Pegram, Mark D., Christina Yeon, Charlene Gottlieb, et al.. (2004). Enzyme catalyzed therapeutic activation of NB1011 (N) selectively targets thymidylate synthase (TS)-overexpressing tumor cells: Phase I results. Journal of Clinical Oncology. 22(14_suppl). 3144–3144. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact